Research News

RSS feed for this section

Partnership with ImmusanT to Promote Phase 2 Clinical Trial of Nexvax2®, A Promising Celiac Disease Treatment

ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease […]

Gluten-Free Diet Does Not Heal Intestinal Damage in 20% of Children With Celiac Disease

A study published November 3, 2016 in the Journal of Pediatric Gastroenterology, found that nearly 20% of children with celiac disease continued to show intestinal damage, despite adhering to a gluten-free diet for one year or more. The study, conducted by researchers at the Celiac Research Program at Harvard Medical School, sought to assess the accuracy […]

Elevated Serology a Red Flag for Men Over 50

Researchers recently screened stored serum samples of over 6,000 individuals who participated in a National Health and Nutrition Examination Survey (NHANES III: 1988-1992). Each sample was tested for IgA anti-tTG and IgA endomysial antibodies, with the intention of determining whether a positive test correlated with increased risk of mortality in those age 50 and older. […]

CDF Presents Patient Advocacy Program Live at the Center for Celiac Research and Treatment 20th Anniversary Celebration and Symposium

On November 4, 2016, Celiac Disease Foundation was invited to present a live session of the Celiac Disease Patient Advocacy Program at the Center for Celiac Research and Treatment 20th Anniversary Celebration and Symposium at Massachusetts General Hospital. CDF CEO, Marilyn Geller, and Communications Manager, Talia Hassid, educated a packed room of people about patient-centered […]

Assessing for Compliance with the Gluten-Free Diet

A new study published online in The American Journal of Gastroenterology used fecal gluten immunogenic peptide (GIP) measurement to assess for patient compliance with the gluten-free diet. Gluten immunogenic peptides are pieces of gluten proteins that don’t get digested and produce immunotoxic reactions in patients with celiac disease. Traditionally, methods used to assess compliance ranged […]